Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroshi Shiku

Showing results (1-10 of 221) with videos related to

Pageof 23
Sort By:
International Journal of Hematology|July 5, 2003
Importance of CD4+ helper T-cells in antitumor immunityHiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 23, 2008
[DNA vaccine]Hiroyoshi Nishikawa, Hiroshi Shiku
Cancer Immunology, Immunotherapy : CII|June 5, 2015
Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytesHiroaki Ikeda, Hiroshi Shiku
Advances in Experimental Medicine and Biology|May 29, 2012
Antigen-receptor gene-modified T cells for treatment of gliomaHiroaki Ikeda, Hiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 25, 2012
[Immunotherapy of solid tumor: perspectives on vaccine and cell therapy]Hiroaki Ikeda, Hiroshi Shiku
Cancer Science|July 13, 2018
Exosome-mediated regulation of tumor immunologyNaohiro Seo, Kazunari Akiyoshi, Hiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 25, 2012
[Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy]Naoko Imai, Hiroaki Ikeda, Hiroshi Shiku
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 8, 2022
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistanceDaisuke Muraoka, Naozumi Harada, Hiroshi Shiku, et al.
European Journal of Immunology|December 18, 2008
Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cellsNaoko Imai, Hiroaki Ikeda, Isao Tawara, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|June 7, 2016
Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC)Hideo Wada, Tsutomu Nobori, Rika Watanabe, et al.
Pageof 23

Showing results (1-10 of 221) with videos related to

Sort By:
Pageof 23
International Journal of Hematology|July 5, 2003
Importance of CD4+ helper T-cells in antitumor immunityHiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 23, 2008
[DNA vaccine]Hiroyoshi Nishikawa, Hiroshi Shiku
Cancer Immunology, Immunotherapy : CII|June 5, 2015
Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytesHiroaki Ikeda, Hiroshi Shiku
Advances in Experimental Medicine and Biology|May 29, 2012
Antigen-receptor gene-modified T cells for treatment of gliomaHiroaki Ikeda, Hiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 25, 2012
[Immunotherapy of solid tumor: perspectives on vaccine and cell therapy]Hiroaki Ikeda, Hiroshi Shiku
Cancer Science|July 13, 2018
Exosome-mediated regulation of tumor immunologyNaohiro Seo, Kazunari Akiyoshi, Hiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 25, 2012
[Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy]Naoko Imai, Hiroaki Ikeda, Hiroshi Shiku
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 8, 2022
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistanceDaisuke Muraoka, Naozumi Harada, Hiroshi Shiku, et al.
European Journal of Immunology|December 18, 2008
Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cellsNaoko Imai, Hiroaki Ikeda, Isao Tawara, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|June 7, 2016
Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC)Hideo Wada, Tsutomu Nobori, Rika Watanabe, et al.
Pageof 23